guidance.fyi
Company, quarter, or anything said on a call

Q1 FY27 earnings callShaily Engineering Plastics Limited

Healthcare, now the largest segment with 85% revenue growth, drove overall performance amid a challenging global environment and softer Consumer demand.

Positive tone4 min readPublished 12 days after the call

Numbers
MetricThis quarterChangeFive-quarter trend
RevenueINR281 crores14%
EBITDAINR83 crores18%
EBITDA Margin29.7%120 bps
PATINR48 crores17%
PAT Margin17.1%40 bps
Healthcare RevenueINR142 crores85%
Consumer RevenueINR116 crores-24%
Industrial RevenueINR23 crores25%
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹197.58 Cr+24.7% YoY+2.9% QoQ₹25.20 Cr+73.6% YoY+15% QoQ₹5.49+73.2% YoY+14.9% QoQ
Q2 FY25₹192.00 Cr+21.9% YoY+7% QoQ₹21.92 Cr+102.4% YoY+25.9% QoQ₹4.78-59.5% YoY+25.8% QoQ
Q1 FY25₹179.39 Cr+14% YoY+5.2% QoQ₹17.41 Cr+38.2% YoY-10% QoQ₹3.80-72.3% YoY-10% QoQ
Q4 FY24₹170.56 Cr+26.8% YoY+7.6% QoQ₹19.34 Cr+94.8% YoY+33.2% QoQ₹4.22-61% YoY+33.1% QoQ
Q3 FY24₹158.44 Cr+16.3% YoY+0.6% QoQ₹14.52 Cr+156.1% YoY+34.1% QoQ₹3.17-48.7% YoY-73.1% QoQ
TL;DR
  • Consolidated revenue grew 14% YoY to INR281 crores, with Healthcare revenue up 85% to INR142 crores.
  • EBITDA grew 18% to INR83 crores, with margin improving 120 bps to 29.7%.
  • PAT grew 17% to INR48 crores.
  • Consumer segment revenue declined 24% YoY due to softer demand in Europe and the U.S.
  • The company expects to exceed its full-year pen injector guidance of 36 million units.
  • New 25 million pen capacity is expected to be operational by end of September.
Said on the call

“Combined with the deliberate effort to hire the best talent in the industry globally, this approach has produced measurable results for Shaily.”

Amit Sanghvi
From the Q&A
TopicWhat management said
Pen Injector Volumes and GuidanceThe company delivered close to 9 million devices in Q1 and expects to exceed its full-year guidance of 36 million pens, subject to customer supply chain conditions.
Capacity Ramp-upA new line's speed has increased by 9% with a plan for a further 30% jump after additional equipment is installed, targeted before the end of the quarter. The next line's strategy involves achieving over 80% efficiency at the supplier before shipment to ensure a smoother start.
Gross Margin PressureSequential gross margin decline was attributed to increased commodity and freight costs, including premium freight incidents; pass-through to customers was delayed into May-June/July, with normalization expected by Q3.
Pricing and CompetitionManagement stated contracts are not cost-plus but are volume and market-driven with annual price reviews; they are not overly concerned about potential Chinese competition pricing devices at $1.50-$1.70 versus their own above $2, citing older technology and patent infringement concerns.
Consumer Electronics and Semiconductor TraysThe company has started commercial supply in Consumer Electronics, won 5 new components from a new customer, and projects reaching $10 million revenue in this vertical within 24 to 30 months. For Semiconductor Trays, an initial INR5 crores investment is planned in the existing facility, with supply expected to start in Q4.
New Healthcare Product DevelopmentManagement is developing an emergency use auto-injector (targeting 99.999% reliability, closure by end of '27), a reusable auto-injector (to be showcased at CPHI Milan), and on-body injectors for oncology treatments.
Abu Dhabi FacilityThe facility is on track for production by the end of FY28, with roughly 50-55% of capacity having commitments or indications.
Guidance
  • Expect to exceed the full-year pen injector guidance of 36 million units.
  • Additional 25 million pen capacity expected to become operational by end of September.
  • Gross margin expected to normalize by Q3 FY27.
  • Consumer business expected to maintain levels similar to FY26, not grow in the current year.
  • Consumer Electronics revenue projected to reach $10 million within 24 to 30 months (not formal guidance).
  • Semiconductor Tray revenue to start in Q4 FY27.
  • Abu Dhabi plant to start commercial sales by end of FY28.
Source
Also this week
  • Gufic Biosciences LimitedQ1 FY27Positive tone

    Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.

    GUFICBIOPharmaceuticals & Healthcare4 min read
  • Dishman Carbogen Amcis LimitedQ1 FY27Positive tone

    Despite a soft revenue quarter, management is focused on sales force expansion, tech transfers to India, and a significant debt refinancing to improve margins, projecting an optimistic future.

    DCALPharmaceuticals & Healthcare3 min read
  • Q1 FY27 saw strong revenue and profit growth driven by scaling service business (Patient Support Programs) and strategic investments beginning to yield results.

    QMSMEDIPharmaceuticals & Healthcare3 min read
  • Natco Pharma LimitedQ1 FY27Positive tone

    Strong profit growth driven by a bumper flu season in the associate Adcock Ingram and double-digit growth in the base business.

    NATCOPHARMPharmaceuticals & Healthcare4 min read
  • IPCA Laboratories LimitedQ1 FY27Positive tone

    Ipca delivered robust 21% revenue growth and significantly improved EBITDA margins by 4.49 percentage points to 22.88%, revising its full-year revenue growth guidance upward.

    IPCALABPharmaceuticals & Healthcare4 min read